This case highlights the need for personalized treatment strategies, and we recommend genetic testing for the R202Q variant in patients with recurrent pericarditis who fail to withdraw from anti-IL-1 therapies; indeed, the therapeutic response observed in this case may not be generalizable to all patients with this variant. This evidence concerns the gene IL1B and pericarditis.